2Sezer JO, Euker J, Schmid R, et al. New therapeutic approaches in primary systemic AL amyloidosis. Ann Hematol, 2000, 79: 1-6.
3Comenzo RL, Vosburgh E, Simms RW, et al. Dose intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one year follow up in five patients. Blood, 1996, 88: 2801-2806.
4Walley VM, Kisilevsky R, Young ID. Amyloid and cardiovascular system: a review of pathogenesis and pathology with clinic correlations. Cardiovascular pathology, 1995, 4:79-102.
1Vucic S, Chong PST, Cros D. Atypical presentations of primary amyloid neuropathy. Muscle Nerve, 2003, 28:696-702.
2Li K, Kyle RA, Dyck PJ. Immunohistochemical characterization of amyloid proteins in sural nerves and clinical associations in amyloid neuropathy. Am J Pathol, 1992, 141:217-226.
3Haan J, Peters WG. Amyloid and peripheral nervous system disease. Am Heart J, 2002, 144:122-129.
4Low PA, Vernino S, Suarez G. Autonomic dysfunction in peripheral nerve disease. Muscle Nerve, 2003, 27:646-661.
5Mendell JR, Kissel JT, Cornblath DR. Diagnosis and management of peripheral nerve disorders. Oxford University Press, 2001, 281-282.
6Abarbanel JM, Frisher S, Osimani A. Primary amyloidosis with peripheral neuropathy and signs of motor neuron disease. Neurology, 1986, 36:1125- 1127.
7Said G. Familial amyloid polyneuropathy:mechanisms leading to nerve degeneration. Amloid, 2003, 10 Suppl 1:7-12.
